Form 10-Q Akebia Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright
August 12, 2024 6:13 AM EDTH.C. Wainwright analyst Ed Arce raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $7.50 (from $6.00) while maintaining a Buy rating.
The analyst comments "Akebia is focused on the long game, with pre-commercial execution preparing for Vafseo as the standard-of-care. As previously announced, Akebia submitted its TDAPA application in June. Akebia expects to have a CPT code assigned in October 2024 and full TDAPA designation by January 1, 2025. In... More
